IRIS
BANDINI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.187
AS - Asia 1.537
NA - Nord America 1.282
SA - Sud America 442
AF - Africa 32
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 5.486
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.218
RU - Federazione Russa 1.199
SG - Singapore 487
CN - Cina 436
BR - Brasile 370
HK - Hong Kong 277
IT - Italia 273
SE - Svezia 249
VN - Vietnam 176
DE - Germania 169
FR - Francia 81
GB - Regno Unito 49
FI - Finlandia 46
IN - India 37
AR - Argentina 34
CA - Canada 32
TR - Turchia 29
PL - Polonia 25
MX - Messico 24
NL - Olanda 23
BD - Bangladesh 17
JP - Giappone 16
ES - Italia 14
ZA - Sudafrica 14
AT - Austria 12
EC - Ecuador 12
IE - Irlanda 12
ID - Indonesia 11
IQ - Iraq 10
LT - Lituania 8
CO - Colombia 7
MA - Marocco 6
PK - Pakistan 6
SA - Arabia Saudita 6
VE - Venezuela 6
PY - Paraguay 5
UA - Ucraina 5
AE - Emirati Arabi Uniti 4
BE - Belgio 4
GR - Grecia 4
MY - Malesia 4
UZ - Uzbekistan 4
CL - Cile 3
EG - Egitto 3
IR - Iran 3
NP - Nepal 3
AL - Albania 2
AU - Australia 2
CZ - Repubblica Ceca 2
EU - Europa 2
GT - Guatemala 2
KE - Kenya 2
KW - Kuwait 2
LV - Lettonia 2
NI - Nicaragua 2
PH - Filippine 2
PT - Portogallo 2
SN - Senegal 2
SR - Suriname 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CH - Svizzera 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GH - Ghana 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LY - Libia 1
MK - Macedonia 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
RS - Serbia 1
UY - Uruguay 1
Totale 5.486
Salva come PNG Salva come JPEG
Città #
Hong Kong 270
Singapore 251
Moscow 226
Dallas 195
Ashburn 175
San Jose 98
Shanghai 94
Milan 89
New York 76
Ho Chi Minh City 71
Hefei 65
Beijing 62
Lawrence 55
Princeton 55
Lauterbourg 54
Los Angeles 50
São Paulo 34
Hanoi 33
Boardman 27
Munich 23
Orem 22
Brooklyn 20
Turin 20
Denver 19
Helsinki 19
Turku 19
Rome 18
Warsaw 17
Montreal 15
Santa Clara 15
Tokyo 14
Poplar 13
Tekirdağ 13
Rio de Janeiro 12
Amsterdam 11
Chennai 11
Dublin 11
London 11
Chicago 10
Frankfurt am Main 10
Manchester 10
Nuremberg 10
Phoenix 10
Boston 9
Da Nang 9
Florence 9
Guangzhou 9
Haiphong 9
Johannesburg 9
Mexico City 8
Seattle 8
Atlanta 7
Caxias do Sul 7
Charlotte 7
Houston 7
Pune 7
Stockholm 7
Vienna 7
Ankara 6
Can Tho 6
Fortaleza 6
Hanover 6
Querétaro 6
Salvador 6
Brasília 5
Bắc Ninh 5
Central 5
Lappeenranta 5
Quito 5
Toronto 5
Bari 4
Betim 4
Cabo Frio 4
Cesano Boscone 4
Detroit 4
Erbil 4
Genoa 4
Guayaquil 4
Livorno 4
Mumbai 4
New Delhi 4
Piracicaba 4
Shenzhen 4
São José 4
Washington 4
Amantea 3
Augusta 3
Baghdad 3
Barnet 3
Barueri 3
Biên Hòa 3
Bologna 3
Buenos Aires 3
Buffalo 3
Cairo 3
Cape Town 3
Carapicuíba 3
Chongqing 3
Columbus 3
Cosenza 3
Totale 2.623
Salva come PNG Salva come JPEG
Nome #
Development of a novel signature integrating clinical, imaging and epigenetic information to tailor pelvic nodal treatment in prostate cancer 348
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab 205
A NOVEL MODEL INTEGRATING CLINICAL, MP-MRI, AND EPIGENOMIC FEATURES TO PREDICT LYMPH NODE INVASION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND PELVIC LYMPH NODE DISSECTION 155
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02 155
Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma 139
A global approach to improving penile cancer care 130
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer 126
Assessing in-hospital morbidity after urethroplasty using the European Association of Urology Quality Criteria for standardized reporting 118
Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma 117
A risk calculator predicting recurrence in lymph node metastatic penile cancer 115
Causal contributors to tissue stiffness and clinical relevance in urology 109
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆ 108
Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration 106
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study) 106
Re: Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-Invasive Bladder Carcinoma with Variant Histologies 102
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy 100
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study 97
DNA methylation alterations in prostate cancer: from diagnosis to treatment 96
Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial 95
Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints 95
Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab? 94
Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus 2020;6:639–41 93
Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study 92
Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer 91
Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups 89
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 89
High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors? 88
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer 87
Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy 83
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand? 83
Topographic modification of the extracellular matrix precedes the onset of bladder cancer 81
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study 79
The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis 70
Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma 68
Targetable gene fusions and aberrations in genitourinary oncology 67
The effect of race on survival after local therapy in metastatic prostate cancer patients 65
Neoadjuvant chemotherapy for lymph node-positive penile cancer: Current evidence and knowledge 65
Revolutionizing care for rare genitourinary tumours 65
Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma 61
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI 60
Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based analysis 60
Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations 60
The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC) 60
Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma 59
Vacuum physiotherapy after first stage buccal mucosa graft (BMG) urethroplasty in children with proximal hypospadias 58
Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. Eur Urol 2020;77:636–43 58
Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm? 57
Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition 57
Salvage pelvic lymph node dissection for lymph node recurrent prostate cancer 56
The new era of precision urobiome: RE: “Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study” by Chipollini et al 56
Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines 55
Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies 55
Nomograms in urologic oncology, advantages and disadvantages 54
Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55–65 53
Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer 52
Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis 51
Prevalence and surgical management of pubic hypertrophy in hypospadias patients: Results from a high-volume surgeon 50
The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer 50
Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? 50
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration 49
Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press: Incidental Prostate Cancer: An Example of How Important Guidelines Are, Especially When Evidence Is Limited 48
Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages 47
Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab 47
Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study 45
Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment 45
Re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. Eur Urol Focus 2020;6:1233–9 44
null 1
null 1
null 1
null 1
null 1
Totale 5.573
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.891
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.891
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202296 0 16 3 32 1 0 2 6 2 4 0 30
2022/2023413 131 99 31 11 3 42 11 46 8 3 13 15
2023/2024365 6 25 38 35 33 67 50 40 4 4 16 47
2024/20251.222 100 50 22 113 49 77 177 165 164 126 65 114
2025/20263.436 227 298 290 447 292 138 262 263 1.084 135 0 0
Totale 5.573